StockData
Polaryx Therapeutics, Inc. logo

Polaryx Therapeutics, Inc. (PLYX) stock

PLYXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 6/30
$1.60−0.07 (-4.19%)

Close on Nov 17, 2026Market cap $79.75MP/E –Yield –

Polaryx Therapeutics enterprise value

Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.

Polaryx Therapeutics's enterprise value was $85.66M on Nov 11, 2026.

Enterprise Value at the end of each year

PeriodPeriod endValueChange
2026Nov 11, 2026$85.66M–

More Polaryx Therapeutics figures

See a number that looks wrong?